Objectives
This study had three aims:
1. To review the use of case series in National
Institute for Clinical Excellence (NICE) Health Technology Assessment (HTA) reports. 2. To review systematically the methodological literature for papers relating to the validity of aspects of case series design. 3. To investigate characteristics and findings of case series using examples from the UK's Health Technology Assessment programme.
Background
Although randomised controlled trials (RCTs) offer the most robust evidence for effectiveness, this level of data is not always available for health technology assessments. Given that policy decisions still need to be made even in the absence of RCT evidence, it is important to try to understand the elements of case series design that determine their quality. Although a simple hierarchy of evidence will place case series as a weak form as evidence, individual studies, just like individual RCTs, may vary widely in quality and different studies of the same intervention may produce widely different estimates of outcome frequency. The validity of any study, whatever its form, will depend on the quality of its design, execution and interpretation. Nevertheless, case series studies are the most vulnerable to bias and confounding. RCTs attempt to minimise challenges to internal validity through minimising selection, performance, detection and attrition biases. However, this may lead to problems of external validity if strict exclusion criteria lead to a population being assessed, which is very different to that treated in clinical practice.
The aspects of quality that influence the validity of RCTs have been empirically studied, and it is generally agreed that adequate blinding, concealment and randomisation methods are crucial. A number of different scales and checklists for quality exist, but not all of them are empirically based or rigorously developed. As the authors were not aware of agreed aspects of quality for case series that were important, this study aimed to look at what types of quality measure had been used in NICE HTAs and to search the literature systematically to see if empirical studies of case series had been published. 
Review of the use of case series in NICE HTAs
Currently completed NICE HTAs were obtained from the NICE website. Of the 47 completed HTAs, 14 (30%) had included information from case series studies.
In two cases no RCTs were identified and the other 12 reports also included data from between two and 70 RCTs. The number of case series included ranged from two to 159. Inclusion criteria for case series included study size and length of follow-up. Various quality criteria were applied (n = 9), with the CRD Report criteria being used in three cases. Data from case series were used to confirm RCT results, to inform an economic model, to explore variation and for meta-analysis.
We found that there was no consensus on which case series to include in HTAs, how to use them or how to assess their quality, despite them being used in 30% of NICE HTAs.
Systematic review of methodological literature
We carried out searches in electronic databases, handsearched journals and examined the
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Executive summary ᭤ bibliographies of papers in order to find studies that assessed aspects of case series design, analysis or quality in relation to study validity. No empirical studies were found. However, it is known that searches that are sensitive enough to identify case series are difficult to design with appropriate specificity and it is possible that we failed to locate such studies.
Investigation of characteristics and findings of case series studies
A number of hypotheses relating to the design of case series studies were developed a priori. These were empirically investigated using four case examples from existing reports produced as part of the UK's HTA programme.
We included HTAs that had at least 40 case series studies available, included at least one goodquality RCT and contained information on the age of participants as a minimum description of the included population. We identified three reports on four topics -functional endoscopic sinus surgery for nasal polyps, spinal cord stimulation for chronic back pain, percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG) for chronic angina.
Data were extracted on outcome measures and study population characteristics.
Analysis was undertaken on a between-study level within each review. For each hypothesis, continuous variable data were explored through scatter plots and robust regression. Regression analysis weighted by sample size were also performed. Binary data were explored through t-tests and Mann-Whitney tests. Analysis of variance (ANOVA) was also performed, weighted for sample size. Multivariate analysis using disease severity, age and male sex was performed using multivariate robust regression or ANOVA as appropriate.
Comparisons between cases series and RCTs were performed using the intervention arms of RCTs as a comparator. There were only enough data to do this for PTCA and CABG. Meta-analysis of RCT data was compared with weighted robust regressions using the intervention as the confounding factor and estimating the coefficient size.
Poor reporting of case series characteristics severely constrained analysis and there were insufficient data to investigate all the hypotheses. Findings were not consistent across the different topics and were subject to considerable uncertainty.
No relationship was found between sample size and outcome frequency. No relationship was found between prospective data collection and outcome frequency. One analysis each (in different topic areas) found a significant association between multi-centre studies and outcome, between independent outcome measurement and outcome frequency and between earlier publication and outcome frequency. Length of follow-up was found to be significantly associated with outcome frequency in three analyses. One topic area had scored case series for quality and this was found to be associated with outcome. However, this quality score contained items which we investigated separately in this review, without evidence of impact.
Compared with RCT evidence, which showed no difference between PTCA and CABG, case series estimates of mortality showed a 1-2% increase in mortality for CABG. For angina recurrence, neither case series nor RCT data showed any difference between the two interventions.
Limitations
We found no previous studies empirically investigating methodological characteristics of case series. However, it is possible that the search strategy failed to find relevant studies.
All the examples in our analysis were surgical interventions, which are prone to additional confounding factors owing to difficulties of standardisation compared with drug treatment. Our findings may not be generalisable outside the interventions studied.
The case series reports included generally exhibited poor reporting of methodological characteristics. This constrained our analysis.
The use of several methods of analysis has led to apparently discrepant results. Given the number of analyses performed, the usual level of significance ( p = 0.05) should be viewed with caution.
The most important limitation of our study is the small number of cases on which our findings are based. The results are therefore tentative and should be viewed with caution. 
Conclusions
Case series are incorporated in a significant proportion of health technology assessments.
A wide range of quality criteria have been used to appraise the quality of case series and decide on their inclusion in reviews of studies using this design. In this small series of case studies drawn from HTAs carried out for the NHS HTA programme, we found little evidence to support the use of many of the factors included in quality assessment tools. Importantly, we found no relationship between study size and outcome across the four examples studied.
Isolated examples of a potentially important relationship between other methodological factors and outcome were shown, such as blinding of outcome measurement, but these were not shown consistently across the small number of examples studied.
Comparison of case series and RCT data was possible in only two examples studied but demonstrated a greater range in outcomes reported in case series, reflecting the likelihood that this design includes different populations. However, outcomes were not better in case series, contrary to expectations.
Estimates of comparative efficacy of alternative techniques by comparing case series studies were shown to be different from analyses based on RCTs. However, it is not clear from this whether this is an effect of confounding or indicates different efficacy in different populations.
This study is based on a very small sample of studies and should therefore be considered as exploratory. Further investigation of the relationship between methodological features and outcome is justified given the frequency of use of case series in health technology assessments.
Need for further research
Further research into the methodological features of case series and their outcome is justified in a wider sample of technologies and larger sets of case series.
Value of information analyses including case series could be explored.
Further exploration of the differences between case series and RCT results, preferably using registry or comprehensive case series data, would be valuable.
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